EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular Profiling of Endocrine Resistance in HR+/HER2-Metastatic Breast Cancer: Insights from Extracellular Vesicles-Derived DNA and ctDNA in Liquid Biopsies

Ana Martínez-Rodríguez, Jesús Fuentes-Antrás, Víctor Lorca iD, Alfonso López de Sá, Pedro Pérez-Segura, Fernando Moreno, Jose Angel García-Sáenz iD, Vanesa García-Barberán iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252313045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Ana Martínez-Rodríguez und 7 weiteren Autor:innen. Beteiligte Einrichtung: "Clinical and Translational Research in Oncology" Group, Molecular Oncology Laboratory, Hospital Clinico San Carlos, Instituto de Investigación Sanit…. Hauptthemen laut MEDLINE: Breast Neoplasms, Extracellular Vesicles, Circulating Tumor DNA, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Asociación Española de Alpinistas con Cáncer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Standard treatments in hormone receptor-positive (HR+)/HER2-metastatic breast cancer (mBC) typically involve endocrine therapy (ET) combined with CDK4/6 inhibitors, yet resistance to ET remains a persistent challenge in advanced cases. A deeper knowledge of the use of liquid biopsy is crucial for the implementation of precision medicine in mBC with real-time treatment guidance. Our study assesses the prognostic value of PIK3CA and ESR1 mutations in DNA derived from extracellular vesicles (EV-DNA) in longitudinal plasma from 59 HR+/HER2-mBC patients previously exposed to aromatase inhibitors, with a comparative analysis against circulating tumor DNA (ctDNA). Mutations were evaluated by digital PCR. PIK3CA and ESR1 mutations were found in 22 and 25% of patients. Baseline ESR1 mutations in EV-DNA were associated with shorter progression-free survival (PFS) across the cohort, with the Y537S mutation showing a particularly strong impact on the outcome of fulvestrant-treated patients. In contrast, PIK3CA mutations in EV-DNA did not significantly correlate with PFS, whereas in ctDNA, they were linked to poor outcomes. Altogether, this study positions EV-DNA as a valuable biomarker alongside ctDNA, enriching the understanding of different analytes in liquid biopsy and supporting strategies for HR+/HER2-mBC in precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsExtracellular VesiclesCirculating Tumor DNAErb-b2 Receptor Tyrosine KinasesClass I Phosphatidylinositol 3-KinasesDrug Resistance, NeoplasmMutationEstrogen Receptor alphaHumansFemaleLiquid BiopsyMiddle AgedAgedBiomarkers, TumorAdultAromatase InhibitorsPrognosisReceptors, EstrogenReceptors, ProgesteroneNeoplasm MetastasisAntineoplastic Agents, Hormonal

Stichwörter der Autor:innen

ESR1PIK3CActDNAendocrine resistanceextracellular vesiclesliquid biopsymetastatic breast cancer

Substanzen

Circulating Tumor DNAErb-b2 Receptor Tyrosine KinasesClass I Phosphatidylinositol 3-KinasesEstrogen Receptor alphaBiomarkers, TumorAromatase InhibitorsReceptors, EstrogenReceptors, ProgesteroneAntineoplastic Agents, HormonalPIK3CA protein, human

Autor:innen und Institutionen

  • "Clinical and Translational Research in Oncology" Group, Molecular Oncology Laboratory, Hospital Clinico San Carlos, Instituto de Investigación Sanitaria Hospital Clinico San Carlos (IdISSC), 28040 Madrid, Spain.
  • Department of Medical Oncology, Hospital Clinico San Carlos, Instituto de Investigación Sanitaria Hospital Clinico San Carlos (IdISSC), 28040 Madrid, Spain.
  • NEXT Oncology Experimental Therapeutics Unit, Hospital Universitario Quironsalud Madrid, 28223 Madrid, Spain.

ORCID-Profile: Víctor Lorca, Jose Angel García-Sáenz, Vanesa García-Barberán

Förderung

  • Asociación Española de Alpinistas con Cáncer

Zitieren

APA

Martínez-Rodríguez, A., Fuentes-Antrás, J., Lorca, V., López de Sá, A., Pérez-Segura, P., Moreno, F., García-Sáenz, J. A., & García-Barberán, V. (2024). Molecular Profiling of Endocrine Resistance in HR+/HER2-Metastatic Breast Cancer: Insights from Extracellular Vesicles-Derived DNA and ctDNA in Liquid Biopsies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252313045

Vancouver

Martínez-Rodríguez A, Fuentes-Antrás J, Lorca V, López de Sá A, Pérez-Segura P, Moreno F, et al. Molecular Profiling of Endocrine Resistance in HR+/HER2-Metastatic Breast Cancer: Insights from Extracellular Vesicles-Derived DNA and ctDNA in Liquid Biopsies. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252313045

BibTeX
@article{MartnezRodrguez2024,
  author = {Martínez-Rodríguez, Ana and Fuentes-Antrás, Jesús and Lorca, Víctor and López de Sá, Alfonso and Pérez-Segura, Pedro and Moreno, Fernando and García-Sáenz, Jose Angel and García-Barberán, Vanesa},
  title = {Molecular Profiling of Endocrine Resistance in HR+/HER2-Metastatic Breast Cancer: Insights from Extracellular Vesicles-Derived DNA and ctDNA in Liquid Biopsies},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252313045}
}
Kostenlos starten →